Vaccine News and Research

Latest Vaccine News and Research

HHS to give states $25 million for HIV drugs; Researchers identify antibodies that may help in AIDS vaccine research

Health and Human Services Secretary Kathleen Sebelius said Thursday "that she would provide $25 million more to help states buy life-saving medications for people with H.I.V. or AIDS. Advocates for patients said the money was not nearly enough to eliminate waiting lists, which have surged to record levels as people have lost health insurance, along with their jobs, and states have cut their budgets. Ms. Sebelius said she was 'reallocating and transferring $25 million in existing resources' to provide medicines for people on waiting lists.

9 Jul 2010

Merck to lay off 15 percent of workers, close plants, research facilities

Drugmaker Merck announced it is closing eight research centers and eight manufacturing plants and laying off 15,000 people from its worldwide operations during the next two years because of its merger with Schering-Plough. "The restructuring is expected to save $2.7 billion to $3.1 billion in 2012, the company said. Meanwhile, the pretax cost of the initial phase of the cost-cutting program is expected to range from $3.5 billion to $4.3 billion, much of it in severance packages for employees."

9 Jul 2010

Merck details global restructuring program

Merck & Co., Inc., known outside the U.S. and Canada as MSD, today provided further detail on integration plans for the company's research and development, manufacturing and other business operations as part of a global restructuring program announced following the November 2009 merger of Merck and Schering-Plough.

9 Jul 2010

WHO report examines donors response to developing countries during H1N1 pandemic

CIDRAP News examines a recently-released WHO report on how donor countries and organizations have responded to the needs of developing countries during the H1N1 (swine flu) pandemic. In September, the WHO estimated the "64 'least-resourced countries' needed a total of $1.48 billion of aid for vaccine, medicines and supplies, laboratory and surveillance services, communications capacity, and other activities to respond to the pandemic," according to the news service.

9 Jul 2010

UC San Diego professor to establish new Peru/Brazil ICEMR to help control malaria

Tropical disease specialist Joseph Vinetz, MD, of the University of California, San Diego School of Medicine will lead an ambitious multi-national effort to help control and eventually conquer malaria, establishing a new Peruvian/Brazilian International Center of Excellence in Malaria Research Center with a seven-year, $9.2 million grant from the National Institutes of Health.

9 Jul 2010

Media outlets examine efforts to tackle HIV/AIDS worldwide

Ahead of the International AIDS Conference, set for July 18-23 in Vienna, Austria, Reuters features an interview with Gottfried Hirnschall, the new director of the WHO's HIV Department, who speaks of the need for current funds for the global HIV/AIDS programs to be used more efficiently to achieve universal access to treatment for all HIV/AIDS patients.

9 Jul 2010

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 70 degrees centigrade.

9 Jul 2010

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Idera Pharmaceuticals, Inc. today announced the issuance of patents covering compositions and methods of using its synthetic immune modulatory oligonucleotides targeted to Toll-like receptors (TLRs). The Company's intellectual property portfolio currently contains over 500 patents and patent applications worldwide and includes claims for TLR-targeted compounds, second-generation antisense chemistry, and oral delivery of certain oligonucleotides.

8 Jul 2010

Increasing HAART treatment for HIV/AIDS patients will provide significant cost savings: Study

Increasing highly active antiretroviral therapy treatment for people with HIV/AIDS will provide significant cost savings over a relatively short period of time, according to a formal economic analysis led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at Providence Health Care and the University of British Columbia.

8 Jul 2010

Study of latest in clinical data technology applied to Phase II clinical trial in South Africa

Last week, at the fourth annual Clinical Trials in Emerging Economies conference, Margaret Ann Snowden, Director of Biostatistics and Data Management at Aeras Global TB Vaccine Foundation, and Daragh Ryan of Cmed Technology, presented a case study of the application of the latest in clinical data technology to a large Phase II clinical trial in South Africa. The presentation provided an update on how effective technology can be in promoting the development of affordable vaccine regimens for the prevention of tuberculosis (TB) worldwide.

8 Jul 2010

MicroRNA-212 plays key role in determining vulnerability to cocaine addiction: Study

Scientists from The Scripps Research Institute have found that a particular type of genetic material plays a key role in determining vulnerability to cocaine addiction and may offer an entirely new direction for the development of anti-addiction therapies. In animal studies, the scientists found that a molecule called microRNA-212 was increased in the brains of test animals that had extended access to cocaine.

8 Jul 2010

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

The Global Alliance for TB Drug Development and Drugs for Neglected Diseases initiative announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world's poor.

8 Jul 2010

Investment report on Hemispherx BioPharma

MicroStockProfit.com announces an investment report featuring Hemispherx BioPharma Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

7 Jul 2010

Northwest Biotherapeutics raises $2.65M during second-quarter

Northwest Biotherapeutics, Inc., developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.

7 Jul 2010

CREW calls for antitrust investigation into drug companies

Today, Citizens for Responsibility and Ethics in Washington (CREW) sent a letter to the Federal Trade Commission (FTC) asking for an antitrust investigation into drug companies that offer significant discounts to doctors for providing patients with only that company's vaccines. CREW sent its letter after learning that Sanofi Pasteur and Merck require physician healthcare groups purchasing their vaccines to enter into contracts prohibiting them from purchasing vaccines made by other companies.

7 Jul 2010

Trigger that induces B cells to produce early, effective antibody response discovered

Researchers at National Jewish Health have discovered a trigger that induces B cells to produce effective and long-lived antibodies early in the immune response. They found that a molecule that binds toll-like receptors doubles the early antibody response to an antigen, and shifts it to a more effective, IgG form.

7 Jul 2010

TWINCORE researchers develop new model approaches for HCV research

The hepatitis C virus is highly specialised. We humans are its natural hosts. The only other living organisms that could be infected with the hepatitis C virus in the lab are chimpanzees. Nevertheless it is - from the viewpoint of the virus - highly successful: around 170 million people are chronically infected with the virus. And with the chronic infection the risk of developing liver cancer also increases.

7 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

WHO H1N1 response probe's second meeting highlights divergent views

The independent team of health experts responsible for reviewing the WHO's response to H1N1 (swine flu) wrapped up a second round of public hearings on Friday, "during which members heard testimony from widely divergent groups, from health officials to some of its most public critics," CIDRAP News reports.

7 Jul 2010

International conference focuses on HPV's impact on women

Scientists, clinicians and public health leaders from around the world are gathered in Montreal this week for the 26th International Papillomavirus Conference where they hope to generate awareness about human papillomavirus, Canwest News Service/Gazette reports (Martin/McCallum, 7/4).

7 Jul 2010

Vaccine News and Research

Latest Vaccine News and Research

HHS to give states $25 million for HIV drugs; Researchers identify antibodies that may help in AIDS vaccine research

Merck to lay off 15 percent of workers, close plants, research facilities

Merck details global restructuring program

WHO report examines donors response to developing countries during H1N1 pandemic

UC San Diego professor to establish new Peru/Brazil ICEMR to help control malaria

Media outlets examine efforts to tackle HIV/AIDS worldwide

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

Idera announces issuance of patents for synthetic immune modulatory oligonucleotides targeted to TLRs

Increasing HAART treatment for HIV/AIDS patients will provide significant cost savings: Study

Study of latest in clinical data technology applied to Phase II clinical trial in South Africa

MicroRNA-212 plays key role in determining vulnerability to cocaine addiction: Study

TB Alliance, DNDi announce inter-PDP agreement to develop potential anti-TB compounds

Investment report on Hemispherx BioPharma

Northwest Biotherapeutics raises $2.65M during second-quarter

CREW calls for antitrust investigation into drug companies

Trigger that induces B cells to produce early, effective antibody response discovered

TWINCORE researchers develop new model approaches for HCV research

QIAGEN receives CE conformity marking for careHPV Test

WHO H1N1 response probe's second meeting highlights divergent views

International conference focuses on HPV's impact on women

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in